Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PHIO PHARMACEUTICALS : PRESENTS NEW IN VIVO DATA AT THE 2021 ASCO ANNUAL MEETING SHOWING DUAL-TARGETING INTASYL OFFERS INCREASED EFFICACY AND SAFETY POTENTIAL OVER OTHER THERAPEUTIC APPROACHES

06/07/2021 | 04:29am EDT

MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced positive in vivo data that provide further evidence on the utility of its INTASYL self-delivering RNAi therapy platform in the field of immuno-oncology. The new study data show how INTASYL can be easily deployed to target multiple proteins and provide evidence of the synergy of the Company's pipeline products. In the study, INTASYL specifically dual-targeting BRD4 and PD-1 elicited complete tumor responses in an in vivo hepatoma model, and significantly outperformed the efficacy of small molecule and antibody treatments towards the same targets.

In this study, the Company assessed the efficacy of mouse/human BRD4-targeting INTASYL PH-894 as monotherapy or co-formulated with mouse PD-1 targeting INTASYL mPH-762, in treating a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice. Positive controls included JQ-1, a small molecule inhibitor of BRD4 and anti-mouse PD-1 monoclonal antibody (mAb) or both treatments.

'We are excited by these new in vivo study results presented at ASCO today, which highlight the potential of INTASYL as a mono- or dual-targeting therapy platform. By using doses that were well below the optimal single agent therapeutic dose identified in previous animal studies, we can obtain very high efficacy by dual-targeting BRD4 and PD-1. Even at these suboptimal concentrations, the dual-targeting INTASYL compound elicited complete responses in 83% of mice, and outperforming JQ-1 and anti-PD-1 mAb treatments, either used individually or in combination. Data from the study also suggests that the dual targeting INTASYL treatment resulted in a superior safety profile, as compared to the JQ-1 and anti-PD-1 mAb treatments,' stated Dr. Simon Fricker, Phio's VP of Research. He added, 'These data further support our message that INTASYL can outperform other therapeutic approaches, and that synergistic drug combination approaches can be easily executed with a single INTASYL formulation.'

A poster further detailing the data presented at the 2021 ASCO Annual Meeting titled 'INTASYL self-delivering RNAi therapy specifically dual-targeting BRD4 and PD-1 elicits complete tumor responses and evidence of synergy in a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice' will be made available on the 'Investors - Events and Presentations' section of the Company's website (click here).

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the coronavirus pandemic, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption 'Risk Factors' and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:

Phio Pharmaceuticals Corp.

E: ir@phiopharma.com

Investor

Ashley R. Robinson

LifeSci Advisors

E: arr@lifesciadvisors.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about PHIO PHARMACEUTICALS CORP.
07/07PHIO PHARMACEUTICALS : Scheduled to Participate in a Fireside Chat with H.C. Wai..
PR
06/22PHIO PHARMACEUTICALS : Reschedules Fireside Chat Hosted by H.C. Wainwright for J..
PR
06/21PHIO PHARMACEUTICALS CORP. : Submission of Matters to a Vote of Security Holders..
AQ
06/14PHIO PHARMACEUTICALS : Scheduled to Participate in Two Upcoming Investor Events ..
PR
06/14PHIO PHARMACEUTICALS : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target ..
MT
06/07PHIO PHARMACEUTICALS : Presents new in vivo data at the 2021 asco annual meeting..
AQ
06/04PHIO PHARMACEUTICALS' : Study Shows Treatment With Intasyl May Induce Tumor Resp..
MT
06/04Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meetin..
CI
05/14PHIO PHARMACEUTICALS : Reports first quarter 2021 financial results and provides..
AQ
05/13PHIO PHARMACEUTICALS CORP. : Results of Operations and Financial Condition, Fina..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -14,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,80x
Yield 2021 -
Capitalization 26,8 M 26,8 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 0,54x
Nbr of Employees 10
Free-Float 99,7%
Chart PHIO PHARMACEUTICALS CORP.
Duration : Period :
Phio Pharmaceuticals Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHIO PHARMACEUTICALS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,98 $
Average target price 6,00 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Gerrit Dispersyn President, Chief Executive Officer & Director
Caitlin Kontulis Secretary, VP-Finance & Administration
Robert J. Bitterman Chairman
Simon Fricker Vice President-Research
James Cardia Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
PHIO PHARMACEUTICALS CORP.-26.39%27
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
IQVIA HOLDINGS INC.39.52%47 899
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-9.68%28 780